Helus Pharma Inc. has announced the appointment of Dr. Suresh Durgam to its Board of Directors, a strategic move aimed at bolstering its leadership in the development of novel serotonergic agonists. This decision is particularly significant as the company seeks to enhance its capabilities in addressing mental health conditions through innovative therapies.

Dr. Durgam brings over two decades of experience in CNS drug development, having previously served as Executive Vice President and Chief Medical Officer at Intra-Cellular Therapies, Inc. His extensive background includes securing FDA approvals for key psychiatric medications and leading clinical development initiatives across various therapeutic areas.

Background

Helus Pharma Inc. operates under the SIC code 2834, which covers Pharmaceutical Preparations. The company, listed on Nasdaq under the ticker HELP, is focused on developing proprietary serotonergic agonists designed to promote neuroplasticity and improve mental health outcomes. Helus Pharma's recent filings include a Form 6-K submitted on October 15, 2026, detailing this leadership change.

What the Filing Says

The filing states, "Helus Pharma Inc. (Nasdaq: HELP) ... today announced the appointment of Suresh Durgam, M.D., to its Board of Directors." This highlights the company's commitment to strengthening its governance and strategic oversight as it progresses toward commercialization of its clinical pipeline.

Impact

Dr. Durgam's appointment is expected to positively influence Helus Pharma's strategic direction, particularly in the development of its proprietary NSAs, which are currently in various stages of clinical trials. His expertise in navigating the regulatory landscape and advancing CNS therapies will be crucial as the company aims to meet its upcoming clinical and regulatory milestones.

What's Next

The filing does not say what happens next, but it is anticipated that Dr. Durgam's appointment will require approval from Cboe Canada, reflecting the company's ongoing efforts to align its governance with industry standards.